{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T04:30:13Z","timestamp":1789446613243,"version":"build-2803163510"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["409156\/2024-8).\u201d"],"award-info":[{"award-number":["409156\/2024-8).\u201d"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003593","name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico","doi-asserted-by":"publisher","award":["409156\/2024-8).\u201d"],"award-info":[{"award-number":["409156\/2024-8).\u201d"]}],"id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019693","name":"Universidade Federal Da Fronteira Sul","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100019693","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Purinergic Signalling"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Pituitary neuroendocrine tumors (PitNETs) constitute a heterogeneous group of intracranial neoplasms with variable biological behavior, whose aggressiveness cannot be explained solely by the intrinsic characteristics of tumor cells. Growing evidence demonstrates that chronic inflammation of the tumor microenvironment (TME) plays a central role in the progression, invasiveness, therapeutic resistance, and recurrence of these tumors. In this context, the purinergic system emerges as a fundamental regulatory axis of the local inflammatory response, integrating signals derived from cellular stress, hypoxia, and metabolic reprogramming. The extracellular release of ATP under conditions of oxidative stress, tissue damage, and cell death serves as a pro-inflammatory signal by activating P2 purinergic receptors. On the other hand, its conversion to adenosine by the ectonucleotidases CD39 and CD73 promotes an immunosuppressive environment, mainly through P1 receptors, such as A2A and A2B. This dynamic balance modulates the infiltration and polarization of immune cells, the production of inflammatory cytokines, including IL-6, IL-8, and TNF-\u03b1, the activation of transcriptional pathways such as NF-\u03baB, STAT3, and HIF-1\u03b1, and extracellular matrix remodeling and angiogenesis. This study aims to review the role of inflammation in the tumor microenvironment of PitNETs, with emphasis on purinergic signaling as an integrating link between oxidative stress, immune dysfunction, and metabolic reprogramming. Although not abundantly explored, the purinergic pathway in PitNETs shows promising potential: it interconnects different elements of the TME, contributes to tumor mechanisms, and is a potential target for immunomodulatory and anti-inflammatory therapies in pituitary tumors.<\/jats:p>","DOI":"10.1007\/s11302-026-10174-2","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T05:57:38Z","timestamp":1783403858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Inflammation, oxidative stress and purinergic signaling in pituitary neuroendocrine tumors (PitNETs)"],"prefix":"10.1007","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-4925-8606","authenticated-orcid":false,"given":"Yenidis Teilor","family":"Scheibel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-1800-4219","authenticated-orcid":false,"given":"Symon","family":"Martins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1516-7595","authenticated-orcid":false,"given":"Andr\u00e9 Paulo","family":"Turcatel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5747-0466","authenticated-orcid":false,"given":"Francini","family":"Franscescon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3813-7139","authenticated-orcid":false,"given":"D\u00e9bora Tavares","family":"de Resende e Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"issue":"7","key":"10174_CR1","doi-asserted-by":"publisher","first-page":"2473","DOI":"10.1210\/jc.2018-00688","volume":"104","author":"J Drummond","year":"2018","unstructured":"Drummond J et al (2018) Clinical and pathological aspects of silent pituitary adenomas. J Clin Endocrinol Metab 104(7):2473\u20132489. https:\/\/doi.org\/10.1210\/jc.2018-00688","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10174_CR2","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1007\/s12022-024-09829-w","volume":"35","author":"M Terry","year":"2024","unstructured":"Terry M et al (2024) High-grade progression, sarcomatous transformation, and\/or metastasis of pituitary neuroendocrine neoplasms (PitNENs): the UCSF experience. Endocrine Pathol 35(4):338\u2013348. https:\/\/doi.org\/10.1007\/s12022-024-09829-w","journal-title":"Endocrine Pathol"},{"key":"10174_CR3","doi-asserted-by":"publisher","unstructured":"Ben-Shlomo A (2023) Exploring the role of the tumor microenvironment in refractory pituitary tumor pathogenesis. Pituitary 26(3):263\u2013265.\u00a0https:\/\/doi.org\/10.1007\/s11102-023-01301-y.\u00a0Springer Science and Business Media LLC","DOI":"10.1007\/s11102-023-01301-y"},{"issue":"5","key":"10174_CR4","doi-asserted-by":"publisher","DOI":"10.1111\/cns.14729","volume":"30","author":"Y Li","year":"2024","unstructured":"Li Y et al (2024) The biological behavior and clinical outcome of pituitary adenoma are affected by the microenvironment. CNS Neurosci Ther 30(5):e14729. https:\/\/doi.org\/10.1111\/cns.14729","journal-title":"CNS Neurosci Ther"},{"key":"10174_CR5","doi-asserted-by":"publisher","unstructured":"Marques P, Grossman A, Korbonits M (2020) The tumour microenvironment of pituitary neuroendocrine tumours. Front Neuroendocrinol 58. https:\/\/doi.org\/10.1016\/j.yfrne.2020.100852","DOI":"10.1016\/j.yfrne.2020.100852"},{"key":"10174_CR6","doi-asserted-by":"publisher","unstructured":"Sabatino ME et al (2018) Oxidative stress and mitochondrial adaptive shift during pituitary tumoral growth. Free Rad Biol Med 120:41\u201355. https:\/\/doi.org\/10.1016\/j.freeradbiomed.2018.03.019","DOI":"10.1016\/j.freeradbiomed.2018.03.019"},{"key":"10174_CR7","doi-asserted-by":"publisher","unstructured":"Zhou Y et al (2023) Oxidative stress in pituitary neuroendocrine tumors: affecting the tumor microenvironment and becoming a new target for pituitary neuroendocrine tumor therapy. CNS Neurosci Ther 29(10):2744\u20132759. https:\/\/doi.org\/10.1111\/cns.14315","DOI":"10.1111\/cns.14315"},{"key":"10174_CR8","doi-asserted-by":"publisher","unstructured":"Huang Z et al (2021) From purines to purinergic signalling: molecular functions and human diseases. Signal Transduct Target Ther 6(1):1\u201320. https:\/\/doi.org\/10.1038\/s41392-021-00553-z","DOI":"10.1038\/s41392-021-00553-z"},{"key":"10174_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00862","volume":"8","author":"M Barber\u00e0-cremades","year":"2017","unstructured":"Barber\u00e0-cremades M et al (2017) P2X7 receptor induces tumor necrosis factor-\u03b1 converting enzyme activation and release to boost TNF-\u03b1 production. Front Immunol 8:862. https:\/\/doi.org\/10.3389\/fimmu.2017.00862","journal-title":"Front Immunol"},{"key":"10174_CR10","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.619458","volume":"11","author":"AL Giuliani","year":"2021","unstructured":"Giuliani AL, Sarti AC, Di Virgilio F (2021) Ectonucleotidases in acute and chronic inflammation. Front Pharmacol 11:619458. https:\/\/doi.org\/10.3389\/fphar.2020.619458","journal-title":"Front Pharmacol"},{"issue":"10","key":"10174_CR11","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1507\/endocrj.EJ21-0106","volume":"68","author":"C Liu","year":"2021","unstructured":"Liu C et al (2021) Emerging role of signal transducer and activator of transcription 3 (STAT3) in pituitary adenomas. Endocr J 68(10):1143\u20131153. https:\/\/doi.org\/10.1507\/endocrj.EJ21-0106","journal-title":"Endocr J"},{"key":"10174_CR12","doi-asserted-by":"publisher","unstructured":"de Oliveira Santos TC, Pereira G, Coutinho AGG, Dos Santos Silva HP, Lima MMS, Dias FAL, de Almeida DC, Resende E Silva DT, Perez RF, Pereira RL. STAT-3 signaling role in an experimental model of nephropathy induced by doxorubicin. Mol Cell Biochem. 2023 May;478(5):981\u2013989. https:\/\/doi.org\/10.1007\/s11010-022-04574-2","DOI":"10.1007\/s11010-022-04574-2"},{"key":"10174_CR13","doi-asserted-by":"publisher","unstructured":"Kameda-Smith M, Lu J (2020) The pituitary tumors and their tumor-specific microenvironment. In: BIRBRAIR, A. (eds.). Tumor microenvironments in organs. Adv Exp Med Biol 1296:117\u2013135. https:\/\/doi.org\/10.1007\/978-3-030-59038-3_7","DOI":"10.1007\/978-3-030-59038-3_7"},{"key":"10174_CR14","doi-asserted-by":"publisher","first-page":"2909","DOI":"10.1038\/ncomms3909","volume":"4","author":"X Ouyang","year":"2013","unstructured":"Ouyang X et al (2013) Adenosine is required for sustained inflammasome activation via the A\u2082A receptor and the HIF-1\u03b1 pathway. Nat Commun 4:2909. https:\/\/doi.org\/10.1038\/ncomms3909","journal-title":"Nat Commun"},{"key":"10174_CR15","doi-asserted-by":"publisher","unstructured":"Villa C et al (2024) Grading and staging for pituitary neuroendocrine tumors. Brain Pathol [S.L.] 35(1):13324.\u00a0https:\/\/doi.org\/10.1111\/bpa.13299.\u00a0Wiley","DOI":"10.1111\/bpa.13299"},{"key":"10174_CR16","doi-asserted-by":"publisher","unstructured":"Carneiro CC, Mendes BB, Bastos LG (2015) ADENOMA HIPOFIS\u00c1RIO: correla\u00e7\u00e3o cl\u00ednica, laboratorial e radiol\u00f3gica. Rev Univ Vale do Rio Verde [S.L.] 13(1):256\u2013269.\u00a0https:\/\/doi.org\/10.5892\/ruvrd.v13i1.1979.\u00a0Universidade Vale do Rio Verde (UninCor)","DOI":"10.5892\/ruvrd.v13i1.1979"},{"issue":"4","key":"10174_CR17","doi-asserted-by":"publisher","first-page":"C5","DOI":"10.1530\/ERC-17-0004","volume":"24","author":"SL Asa","year":"2017","unstructured":"Asa SL et al (2017) From pituitary adenoma to pituitary neuroendocrine tumor (PitNET): an International Pituitary Pathology Club proposal. Endocrine-Relat Cancer 24(4):C5\u2013C8. https:\/\/doi.org\/10.1530\/ERC-17-0004","journal-title":"Endocrine-Relat Cancer"},{"key":"10174_CR18","doi-asserted-by":"publisher","unstructured":"Daly A, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am [S.L.] 49(3):347\u2013355.\u00a0https:\/\/doi.org\/10.1016\/j.ecl.2020.04.002.\u00a0Elsevier BV","DOI":"10.1016\/j.ecl.2020.04.002"},{"key":"10174_CR19","doi-asserted-by":"publisher","unstructured":"Osorio R\u00a0et al (2022)\u00a0Pituitary adenomas and cerebrovascular disease: a review on pathophysiology, prevalence, and treatment. Front Endocrinol\u00a013:1064216. https:\/\/doi.org\/10.3389\/fendo.2022.1064216","DOI":"10.3389\/fendo.2022.1064216"},{"key":"10174_CR20","doi-asserted-by":"publisher","unstructured":"Iglesias P, Berrocal VR, D\u00edez JJ (2018) Giant pituitary adenoma: histological types, clinical features and therapeutic approaches. Endocrine\u00a0[S.L.] 61(3):407\u2013421.\u00a0https:\/\/doi.org\/10.1007\/s12020-018-1645-x.\u00a0Springer Science and Business Media LLC","DOI":"10.1007\/s12020-018-1645-x"},{"key":"10174_CR21","doi-asserted-by":"publisher","unstructured":"Fistarol G et al (2025)\u00a0Dysregulation of purinergic signaling sustains chronic inflammation and oxidative imbalance in patients after PitNET surgical resection. Int J Mol Sci 26(14):6890. https:\/\/doi.org\/10.3390\/ijms26146890","DOI":"10.3390\/ijms26146890"},{"key":"10174_CR22","doi-asserted-by":"publisher","unstructured":"Giuliani AL\u00a0et al (2019)\u00a0Extracellular nucleotides and nucleosides as signalling molecules. Immunol Lett\u00a0[S.L.] 205:16\u201324.\u00a0https:\/\/doi.org\/10.1016\/j.imlet.2018.11.006.\u00a0Elsevier BV","DOI":"10.1016\/j.imlet.2018.11.006"},{"key":"10174_CR23","doi-asserted-by":"publisher","unstructured":"Burnstock G et al (2018) Purine and purinergic receptors. Brain Neurosci Adv [S.L.] 2. https:\/\/doi.org\/10.1177\/2398212818817494. SAGE Publications","DOI":"10.1177\/2398212818817494"},{"key":"10174_CR24","doi-asserted-by":"publisher","unstructured":"Virgilio F di, Adinolfi E (2016) Extracellular purines, purinergic receptors and tumor growth. Oncogene [S.L.] 36(3):293- 303.\u00a0https:\/\/doi.org\/10.1038\/onc.2016.206.\u00a0Springer Science and Business Media LLC","DOI":"10.1038\/onc.2016.206"},{"key":"10174_CR25","doi-asserted-by":"publisher","unstructured":"Borrmann T\u00a0et al (2009)\u00a0Structure\u2212activity relationships of adenine and deazaadenine derivatives as ligands for adenine receptors, a new purinergic receptor family. J Med Chem\u00a0[S.L.] 52(19):5974\u20135989.\u00a0https:\/\/doi.org\/10.1021\/jm9006356.\u00a0American Chemical Society (ACS)","DOI":"10.1021\/jm9006356"},{"key":"10174_CR26","doi-asserted-by":"crossref","unstructured":"Fredholm BB et al (2001) International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev 53(4):527\u2013552. dez. 2001. Dispon\u00edvel em: https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC9389454\/","DOI":"10.1016\/S0031-6997(24)01511-4"},{"key":"10174_CR27","doi-asserted-by":"publisher","unstructured":"Verkhrastsky A\u00a0et al (2014)\u00a0Biology of purinergic signalling: its ancient evolutionary roots, its omnipresence and its multiple functional significance. Bioessays\u00a0[S.L.] 36(7):697\u2013705.\u00a0https:\/\/doi.org\/10.1002\/bies.201400024.\u00a0Wiley","DOI":"10.1002\/bies.201400024"},{"key":"10174_CR28","doi-asserted-by":"publisher","unstructured":"Dalagnol AMK, Franscescon F, Bianchini MC\u00a0et al (2026)\u00a0Resistance exercise exerts anti-hypertensive effects and downregulates NTPDase\/CD39 and ecto-5\u2032-nucleotidase\/CD73 expression in patients with chronic kidney disease undergoing hemodialysis.\u00a0Purinergic Signal\u00a022:11. https:\/\/doi.org\/10.1007\/s11302-025-10121-7","DOI":"10.1007\/s11302-025-10121-7"},{"issue":"2","key":"10174_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1007\/s11302-005-5303-4","volume":"2","author":"C Stefan","year":"2006","unstructured":"Stefan C, Jansen S, Bollen M (2006) Modulation of purinergic signaling by NPP-type ectophosphodiesterases. Purinergic Signal 2(2):361\u2013370. https:\/\/doi.org\/10.1007\/s11302-005-5303-4","journal-title":"Purinergic Signal"},{"issue":"9","key":"10174_CR30","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.tem.2009.05.005","volume":"20","author":"S Stojilkovic","year":"2009","unstructured":"Stojilkovic S (2009) Purinergic regulation of hypothalamopituitary functions. Trends Endocrinol Metab 20(9):460\u2013468. https:\/\/doi.org\/10.1016\/j.tem.2009.05.005","journal-title":"Trends Endocrinol Metab"},{"issue":"2","key":"10174_CR31","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s40618-024-02445-9","volume":"48","author":"H Yin","year":"2025","unstructured":"Yin H et al (2025) Pannexin-1 regulation of ATP release promotes the invasion of pituitary adenoma. J Endocrinol Investig 48(2):317\u2013332. https:\/\/doi.org\/10.1007\/s40618-024-02445-9","journal-title":"J Endocrinol Investig"},{"issue":"1","key":"10174_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.immuni.2017.06.020","volume":"47","author":"F Di Virgilio","year":"2017","unstructured":"Di Virgilio F et al (2017) The P2X7 receptor in infection and inflammation. Immunity 47(1):15\u201331. https:\/\/doi.org\/10.1016\/j.immuni.2017.06.020","journal-title":"Immunity"},{"issue":"3","key":"10174_CR33","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1124\/pr.117.014878","volume":"71","author":"L Antonioli","year":"2019","unstructured":"Antonioli L et al (2019) The purinergic system as a pharmacological target for the treatment of immune-mediated inflammatory diseases. Pharmacol Rev 71(3):345\u2013382. https:\/\/doi.org\/10.1124\/pr.117.014878","journal-title":"Pharmacol Rev"},{"key":"10174_CR34","doi-asserted-by":"publisher","unstructured":"Virgilio F di, Schmalzing G, Markwardt F (2018) The elusive P2X7 macropore. Trends Cell Biol\u00a028(5):392\u2013404. https:\/\/doi.org\/10.1016\/j.tcb.2018.01.005","DOI":"10.1016\/j.tcb.2018.01.005"},{"key":"10174_CR35","doi-asserted-by":"publisher","unstructured":"Virgilio F di\u00a0et al (2021)\u00a0P2X receptors in cancer growth and progression. Biochem Pharm\u00a0187:114350.\u00a0https:\/\/doi.org\/10.1016\/j.bcp.2020.114350","DOI":"10.1016\/j.bcp.2020.114350"},{"issue":"11","key":"10174_CR36","doi-asserted-by":"publisher","first-page":"2496","DOI":"10.3390\/cells9112496","volume":"9","author":"V Vultaggio-Poma","year":"2020","unstructured":"Vultaggio-Poma V, Sarti AC, di Virgilio F (2020) Extracellular ATP: a feasible target for cancer therapy. Cells 9(11):2496. https:\/\/doi.org\/10.3390\/cells9112496","journal-title":"Cells"},{"issue":"52","key":"10174_CR37","doi-asserted-by":"publisher","first-page":"44776","DOI":"10.1074\/jbc.M111.289793","volume":"286","author":"K Isfort","year":"2011","unstructured":"Isfort K et al (2011) Real-time imaging reveals that P2Y2 and P2Y12 receptor agonists are not chemoattractants and macrophage chemotaxis to complement C5a is phosphatidylinositol 3-kinase (PI3K)- and p38 mitogen-activated protein kinase (MAPK)- independent. J Biol Chem 286(52):44776\u201387. https:\/\/doi.org\/10.1074\/jbc.M111.289793","journal-title":"J Biol Chem"},{"key":"10174_CR38","doi-asserted-by":"publisher","unstructured":"Lu M, Wang Y, Zhan X (2019) The MAPK pathway-based drug therapeutic targets in pituitary adenomas. Front Endocrinol 10. https:\/\/doi.org\/10.3389\/fendo.2019.00330","DOI":"10.3389\/fendo.2019.00330"},{"key":"10174_CR39","doi-asserted-by":"publisher","unstructured":"Derwich A\u00a0et al (2023)\u00a0The role of activation of PI3K\/AKT\/mTOR and RAF\/MEK\/ERK pathways in aggressive pituitary adenomas\u2014 new potential therapeutic approach\u2014a systematic review. Int J Mol Sci\u00a024(13):10952. https:\/\/doi.org\/10.3390\/ijms241310952","DOI":"10.3390\/ijms241310952"},{"key":"10174_CR40","doi-asserted-by":"publisher","unstructured":"Stojilkovic SS et al (2017) Ion channels of pituitary gonadotrophs and their roles in signaling and secretion. Front Endocrinol 8(126). https:\/\/doi.org\/10.3389\/fendo.2017.00126","DOI":"10.3389\/fendo.2017.00126"},{"key":"10174_CR41","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s11302-013-9396-x","volume":"10","author":"G Burnstock","year":"2014","unstructured":"Burnstock G (2014) Purinergic signalling in endocrine organs. Purinergic Signal 10:189\u2013231. https:\/\/doi.org\/10.1007\/s11302-013-9396-x","journal-title":"Purinergic Signal"},{"key":"10174_CR42","doi-asserted-by":"publisher","unstructured":"Maj T\u00a0et al (2017)\u00a0Oxidative stress controls regulatory T cell apoptosis and suppressor activity and PD-L1-blockade resistance in tumor. Nat Immunol 18:1332\u20131341. https:\/\/doi.org\/10.1038\/ni.3868","DOI":"10.1038\/ni.3868"},{"key":"10174_CR43","doi-asserted-by":"publisher","unstructured":"Vela-Pati\u00f1o S\u00a0et al (2024)\u00a0The immune microenvironment landscape of pituitary neuroendocrine tumors, a transcriptomic approach. Genes 15(5):531. https:\/\/doi.org\/10.3390\/genes15050531","DOI":"10.3390\/genes15050531"},{"key":"10174_CR44","doi-asserted-by":"publisher","unstructured":"Su W et al (2025) Single-cell and spatial transcriptome analyses reveal tumor heterogeneity and immune remodeling involved in pituitary neuroendocrine tumor progression. Nat Commun 16(5007). https:\/\/doi.org\/10.1038\/s41467-025-60028-5","DOI":"10.1038\/s41467-025-60028-5"},{"key":"10174_CR45","doi-asserted-by":"publisher","unstructured":"Mei Y et al (2021) Immune profiling of pituitary tumors reveals variations in immune infiltration and checkpoint molecule expression. Pituitary 24:359\u201337. https:\/\/doi.org\/10.1007\/s11102-020-01114-3","DOI":"10.1007\/s11102-020-01114-3"},{"key":"10174_CR46","doi-asserted-by":"publisher","unstructured":"Yu Q\u00a0et al (2011)\u00a0Expression of P2Y receptors in the rat anterior pituitary. Purinergic Signal\u00a07:207\u2013219. https:\/\/doi.org\/10.1007\/s11302-011-9236-9","DOI":"10.1007\/s11302-011-9236-9"},{"key":"10174_CR47","doi-asserted-by":"publisher","unstructured":"Zhao W\u00a0et al\u00a0(2020) Expression of P2X receptors in the rat anterior pituitary. Purinergic Signal\u00a016:17\u201328. https:\/\/doi.org\/10.1007\/s11302-019-09685-y","DOI":"10.1007\/s11302-019-09685-y"},{"issue":"1","key":"10174_CR48","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbrc.2012.02.122","volume":"420","author":"A Kawano","year":"2012","unstructured":"Kawano A et al (2012) Regulation of P2X7-dependent inflammatory functions by P2X4 receptor in mouse macrophages. Biochem Biophys Res Commun 420(1):102\u2013107. https:\/\/doi.org\/10.1016\/j.bbrc.2012.02.122","journal-title":"Biochem Biophys Res Commun"},{"key":"10174_CR49","doi-asserted-by":"publisher","unstructured":"Klaunig J (2018) Oxidative stress and cancer. Curr Pharm Des 24(40):4771\u20134778. https:\/\/doi.org\/10.2174\/1381612825666190215121712","DOI":"10.2174\/1381612825666190215121712"},{"issue":"10","key":"10174_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3390\/cells9102202","volume":"9","author":"K Chun","year":"2020","unstructured":"Chun K, Jang J, Kim D (2020) Perspectives regarding the intersections between STAT3 and oxidative metabolism in cancer. Cells 9(10):29. https:\/\/doi.org\/10.3390\/cells9102202","journal-title":"Cells"},{"issue":"3","key":"10174_CR51","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.cell.2012.01.021","volume":"148","author":"GL Semenza","year":"2012","unstructured":"Semenza GL (2012) Hypoxia-inducible factors in physiology and medicine. Cell 148(3):399\u2013408. https:\/\/doi.org\/10.1016\/j.cell.2012.01.021","journal-title":"Cell"},{"issue":"17","key":"10174_CR52","doi-asserted-by":"publisher","first-page":"10037","DOI":"10.3390\/ijms231710037","volume":"23","author":"A Fukushi","year":"2022","unstructured":"Fukushi A et al (2022) Revisited metabolic control and reprogramming cancers by means of the Warburg effect in tumor cells. Int J Mol Sci 23(17):10037. https:\/\/doi.org\/10.3390\/ijms231710037","journal-title":"Int J Mol Sci"},{"key":"10174_CR53","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.coph.2016.04.001","volume":"29","author":"B Allard","year":"2016","unstructured":"Allard B et al (2016) Immunosuppressive activities of adenosine in cancer. Curr Opin Pharm Cancer IM 29:7\u201316. https:\/\/doi.org\/10.1016\/j.coph.2016.04.001","journal-title":"Curr Opin Pharm Cancer IM"},{"key":"10174_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2021.102137","volume":"47","author":"LEB Savio","year":"2021","unstructured":"Savio LEB et al (2021) Purinergic signaling in the modulation of redox biology. Redox Biol 47:102137. https:\/\/doi.org\/10.1016\/j.redox.2021.102137","journal-title":"Redox Biol"},{"issue":"17","key":"10174_CR55","doi-asserted-by":"publisher","first-page":"11632","DOI":"10.1021\/acs.jmedchem.3c00770","volume":"66","author":"A Cipriano","year":"2023","unstructured":"Cipriano A et al (2023) NADPH Oxidases: from molecular mechanisms to current inhibitors. J Med Chem 66(17):11632\u201311655. https:\/\/doi.org\/10.1021\/acs.jmedchem.3c00770","journal-title":"J Med Chem"},{"issue":"6","key":"10174_CR56","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1089\/ars.2013.5549","volume":"21","author":"SS Stojilkovic","year":"2014","unstructured":"Stojilkovic SS et al (2014) Regulation of ATP-gated P2X channels: from redox signaling to interactions with other proteins. Antioxid Redox Signal 21(6):953\u2013970. https:\/\/doi.org\/10.1089\/ars.2013.5549","journal-title":"Antioxid Redox Signal"},{"issue":"1","key":"10174_CR57","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.bbrc.2012.02.122","volume":"420","author":"A Kawano","year":"2012","unstructured":"Kawano A et al (2012) Regulation of P2X7-dependent inflammatory functions by P2X4 receptor in mouse macrophages. Biochem Biophys Res Commun 420(1):102\u2013107. https:\/\/doi.org\/10.1016\/j.bbrc.2012.02.122","journal-title":"Biochem Biophys Res Commun"},{"key":"10174_CR58","doi-asserted-by":"publisher","unstructured":"Resende e Silva DT, Bizuti MR, de Oliveira NR, Lima LZM, Dos Santos Arraes VG, Zietz ACG, Zin C, de Sousa Silva GV, Puhle JG, Haag FB (2024) Physical exercise as a modulator of the purinergic system in the control of sarcopenia in individuals with chronic kidney disease on hemodialysis. Purinergic Signal 20(3):213\u2013222. https:\/\/doi.org\/10.1007\/s11302-023-09950-1","DOI":"10.1007\/s11302-023-09950-1"},{"key":"10174_CR59","doi-asserted-by":"publisher","unstructured":"Holmstr\u00f6m KM, Finkel T (2014) Cellular mechanisms and physiological consequences of redox-dependent signalling. Nat Rev Mol Cell Biol 15(6):411\u2013421.https:\/\/doi.org\/10.1038\/nrm3801.","DOI":"10.1038\/nrm3801"},{"key":"10174_CR60","doi-asserted-by":"publisher","unstructured":"Sapochnik M, Fuertes M, Arzt E (2017) Programmed cell senescence: role of IL-6 in the pituitary. J Mol Endocrinol. https:\/\/doi.org\/10.1530\/JME-17-0026","DOI":"10.1530\/JME-17-0026"},{"key":"10174_CR61","doi-asserted-by":"publisher","unstructured":"Aguiar CF, Naffah-de-Souza C, Castoldi A, Corr\u00eaa-Costa M, Braga TT, Naka \u00c9L, Amano MT, Abate DT, Hiyane MI, Cenedeze MA, Pacheco e Silva Filho A, C\u00e2mara NO (2015) Administration of \u03b1-galactosylceramide improves adenine-induced renal injury. Mol Med 21(1):553\u201362. https:\/\/doi.org\/10.2119\/molmed.2014.00090","DOI":"10.2119\/molmed.2014.00090"}],"container-title":["Purinergic Signalling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11302-026-10174-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11302-026-10174-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:08:26Z","timestamp":1787576906000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11302-026-10174-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10174"],"URL":"https:\/\/doi.org\/10.1007\/s11302-026-10174-2","relation":{},"ISSN":["1573-9538","1573-9546"],"issn-type":[{"value":"1573-9538","type":"print"},{"value":"1573-9546","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]},"assertion":[{"value":"16 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Conflict of interests","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}],"article-number":"62"}}